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ABSTRACT
There is an increasing awareness that the gut microbiome plays a critical role in human health and disease, but
mechanistic insights are often lacking. In June 2018, the Health and Environmental Sciences Institute (HESI) held a
workshop, “The Gut Microbiome: Markers of Human Health, Drug Efficacy and Xenobiotic Toxicity” (https://hesiglobal.org/
event/the-gut-microbiome-workshop) to identify data gaps in determining how gut microbiome alterations may affect
human health. Speakers and stakeholders from academia, government, and industry addressed multiple topics including
the current science on the gut microbiome, endogenous and exogenous metabolites, biomarkers, and model systems. The
Published by Oxford University Press on behalf of the Society of Toxicology 2020.
This work is written by US Government employees and is in the public domain in the US.
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workshop presentations and breakout group discussions formed the basis for identifying data gaps and research needs.
Two critical issues that emerged were defining the microbial composition and function related to health and developing
standards for models, methods and analysis in order to increase the ability to compare and replicate studies. A series of key
recommendations were formulated to focus efforts to further understand host-microbiome interactions and the
consequences of exposure to xenobiotics as well as identifying biomarkers of microbiome-associated disease and toxicity.
Key words: microbiome; gut; health; xenobiotics; environmental; biotransformation; biomarkers; animal models.

The gastrointestinal (GI) microbiota play an underlying role in
health. Alterations in stability and functional capabilities of
microbiota are associated with disease although is unclear
whether this is a cause or a result of the disease. Although there
is emerging research regarding the physiological functions of
intestinal microbes, less is known about the consequences of
chemically induced alterations to intestinal microbiome composition and toxicological effects to the host. The interactions
of xenobiotics with the microbiota as a result of drug therapy or
environmental exposures are of increasing interest to public
health.
Health and Environmental Sciences Institute (HESI) assembled a cross-disciplinary group of experts (Table 1) to examine
gut microbial-host dynamics in order to better understand what
is currently known about the effect of chemical exposures on
the microbiome and to identify key knowledge gaps related to
such exposures (Figure 1).

KEY ISSUE NO. 1: DEFINING GUT
MICROBIOMES ASSOCIATED WITH HEALTH
The intestinal microbiome is made up of between 500 and 1000
bacterial species as well as viruses, archaea, and eukaryotic
microorganisms, many of which play a role in human health
and disease (Backhed et al., 2012; Gilbert et al., 2018; Hanson and
Weinstock, 2016; Ogilvie and Jones, 2015; Qin et al., 2010;
Tuddenham and Sears, 2015; Virgin, 2014; Ward et al., 2018).
There is great variation in species diversity, taxonomic

composition, and population density of microbiota in the gut of
humans and animal species. For those taxa that contribute to
human health little is known about the part that each microbial
species is filling, how well they perform that function, their
interactions with other microorganisms and with the host, and
where in the host they are acting (Backhed et al., 2012; Barratt
et al., 2017; Cho and Blaser, 2012; Gilbert et al., 2018).
Understanding the functions, features and normal ranges of the
microbial communities that support health will be essential in
addressing impacts of environmental agents and potentially
identifying microbial configurations that result in disease
(Lloyd-Price et al., 2016, 2019). The inclusion of functional measurements may lead to different interpretations of microbiota diversity, compared with taxonomic classification alone, leading
to greater analytical challenges (Fu et al., 2016; Zhu et al., 2015).
However, there is a growing consensus that functional characterizations are necessary for understanding and modeling the
physiology of the microbiome (Heintz-Buschart and Wilmes,
2018; Moya and Ferrer, 2016; Zhu et al., 2015).
Before beneficial or adverse effects of chemical exposure can
be determined, it is necessary to have a baseline for the bacterial species diversity as well as an understanding of the functional capacities associated with health. Given the considerable
variation across human populations, among individuals and
even within an individual, this will not be a single microbiome
but a group of features, capabilities and characteristics of microbial communities that contribute to health. In defining such
microbiomes, temporal variability in these communities, such
as short-term perturbations associated with diet, lifestyle traits,

Table 1. Workshop Topics and Presenters
Workshop Topics
Drugging gut microbial enzymes for treatment of CVD
Biotransformation

Biomarkers of adverse effects

Biomarkers of toxicity and disease

Human susceptibility

Animal models

Expert Presenters
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Mark Brown, Cleveland Clinic
Julia Cui, University of Washington
Gary Perdew, Penn State University
Andrew Patterson, Penn State University
Rod Dietert, Cornell University
Carrie Brodmerkel, Janssen
Carl Cerniglia, US FDA-NCTR
Joseph Petrosino, Baylor College of Medicine
Kun Lu, University of North Carolina Chapel Hill
Emily Hollister, Diversigen
Elaine Richards Sumners, University of Florida
Nathan Price, Institute for Systems Biology
Eugene Chang, University of Chicago
Marijke Faas, University of Groningen
Aaron Ericsson, University of Missouri
Barbara Rehermann, NIH/NIDDK
Tamara Tal, U.S. EPA

Experts from all sectors addressed state of the science and need for identification of biomarkers to advance understanding and decision making on efficacy and safety
of xenobiotics. Presentations can be found on the HESI website here (https://hesiglobal.org/event/the-gut-microbiome-workshop/).
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Figure 1. Key data gaps in the microbiome research field identified at the 2018 HESI workshop. HESI’s June 2018 workshop identified key data gaps in the gut microbiome research field. The results identify needs for easily accessible biomarkers and improved human and animal experimental model studies for testing and validation of the impact of changes in the gut microbiome on human health outcomes.

antibiotic exposure, or acute illness, as well as more long-term
impacts that may lead to deleterious chronic health outcomes
must be considered (Kundu et al., 2017). In addition, factors such
as geographic location, ethnicity, age, physical activity, genetics
and gender, resistance (the ability to withstand stress or perturbations), and resilience (the capacity to return to a healthy
state) influence an individual’s microbiome (Backhed et al,
2012). For example, diet is associated with significant differences in microbiota both across populations and with longitudinal
studies, yet there may not be apparent adverse impacts to human health (Clemente et al, 2015; Yatsunenko et al, 2012). Such
observations suggest that there may be functional redundancy
in biochemical pathways in the microbiome (Baumler and
Sperandio, 2016). Large cohort studies may be needed in defining normal variations within a microbiome, especially if the
studies include longitudinal sampling of the microbiome (Faust
et al., 2015; Fettweis et al. 2019; Flores et al., 2014; Lloyd-Price
et al., 2019; Proctor et al., 2019; Vandeputte et al., 2017a,b;
Yassour et al., 2016; Zhou et al., 2019). Measurement of blood
metabolome is useful in predicting gut a-diversity in such studies (Price et al., 2017; Wilmanski et al., 2019).
For most healthy adults, there appears to be a window of
microbiome normalcy whose bounds are not typically
exceeded, even though there may be minor transitory variation
in composition observed with dietary changes or exposures to
certain xenobiotics (Kundu et al., 2017; Moya and Ferrer, 2016).
However, changes in microbial communities can be associated
with adverse health consequences. In one model, this may occur if a person’s microbiome leaves their respective window of
normalcy reaching a “tipping point” where their health is affected. Alternatively, rather than a distinct shift there can be
stochastic changes in the microbiome leading to dispersion of
the microbiome composition as well as increased functions that
are related to disease (Armour et al., 2019; Zaneveld et al. 2017).

RESEARCH NEED NO. 1
In order to understand, adverse health effects of the microbiome resulting from disease or xenobiotic exposure, there is a
need to better understand the essential components,

capabilities, and range of microbial variation linked to a person’s health. This requires comprehension of both the structure
and the function of the microbial community. Identification of
key conserved functional, metabolic, and biochemical pathways
present in healthy individuals may provide a strong starting
point.
It is evident that multiple factors contribute to the composition, diversity and function of the gut microbiome with regard
to health, drug efficacy, and xenobiotic toxicity. The list
includes genetics, diet, age, obesity, concomitant diseases,
drugs, and gender to name a few. There is a need to not only understand the impact of a single factor on the dynamics between
gut microbiome and the host but also to determine contributions of combinations of these factors. However, defining what
constitutes microbial diversity and functionally of both healthy
and unhealthy individuals will help to elucidate the relative
contributions of host factors.
Large cohort studies are valuable sources of data for defining
microbiomes associated with health, but comparison and reproducibility across such studies is hindered by differences in experimental design and data analysis. Variation and bias in
sampling procedures, stabilization conditions, shipment and
storage practices, methods for analyte extraction and purification, sample preparation and analysis, bioinformatic analysis
algorithms as well as the reference databases used are contributing factors (Backhed et al., 2012; Gilbert et al., 2018; Sinha et al.,
2017; Stulberg et al., 2016). Standardization of methods and analytical approaches is needed to develop a well-characterized
measurement pipeline. However, procedures may need to remain somewhat fluid to account for continuing technological
developments and evolving understanding of the biology
involved.

KEY ISSUE NO. 2: DEFINING CAUSES AND
EFFECTS OF ALTERING THE GUT MICROBIOME
GI microbiota are essential in maintaining health and wellness
by digesting food nutrients, producing endogenous metabolites
and biotransforming xenobiotics (Dietert and Silbergeld, 2015b).
Furthermore, in a healthy individual the gut microbiome,
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together with the intestinal mucosa, is necessary to maintain gut
homeostasis and provide an epithelial barrier between the lumen
and the rest of the body (Hiippala et al., 2018; Rogers, 2015).
Loss, disruption or dispersion of a functional microbiome can
be associated with acute adverse health effects or chronic diseases. For example, antibiotics can alter a healthy individual’s
microbiome resulting in diarrhea, leaving the body susceptible to
the development of Clostridium difficile infection (Backhed et al.,
2012; Schaffler and Breitruck, 2018; Schubert et al., 2014). Changes
in gut microbiota may be linked to the development of inflammatory bowel disease, colorectal cancer, and fatty liver disease
(Miyoshi et al., 2017; Sharpton et al., 2019; Wang et al., 2017).
Many of these chronic diseases have inflammatory or altered immune system characteristics. Critical immune functions related to epithelial signaling, inflammatory responses,
production of antimicrobial factors, and induction of
Immunoglobulin A antibodies are propagated locally in the GI
tract and associated secondary lymphoid tissues (Peyer’s
Patches; Baumler and Sperandio, 2016; Dietert and Dietert,
2015a; Hiippala et al., 2018). The microbiome contributes to the
development and maintenance of the immune system (Agace
and McCoy, 2017). Early life is characterized by a period of microbial flux and assembly which is affected by multiple factors
such as manner of delivery (vaginal or c-section), nutrition
(breast milk or formula) and antibiotic exposure. Although dynamic in nature, in adults the majority of the composition and
function of the microbiome of a healthy person is fairly stable,
but this decreases with age due to the loss of key species and a
progressive gain of pathobiotic bacteria (Buford, 2017).
The systemic influence of the GI microbiota on human
health can be altered by exogenous compounds during drug
therapy or environmental exposures. Antibiotics are used to remove a pathogen from the host, but an unintended consequence can be alteration of the composition and function of the
gut microbiota (Miyoshi et al., 2017). Exposure to nicotine, arsenic, or polybrominated diphenyl ethers change the gut microbiome diversity (Chi et al., 2017, 2018; Li et al., 2018).
Exposure to xenobiotics can have effects in multiple ways.
These include those that are transitory, established, or developmentally programmed (Dietert and Dietert, 2015a; Faust et al.,
2015; Fofanova et al., 2016; Moya and Ferrer, 2016; Norman et al.,
2015; Pascal et al., 2017; Sanz et al., 2015; Stenman et al., 2016).
The transitory outcomes, such as changes after eating, are typically easily correctable and the gut microbiome return to the
composition and functionality exhibited before the insult.
Established outcomes occur when there is the alteration of a keystone species within the microbiota which would require significant host and microbiota changes to recover the original
microbiota (eg, after C. difficile infection). The developmentally programmed outcomes are those that occur when the adverse impact is the result of alteration during a critical window of the
microbiome development and can lead to later-in-life problems
associated with the microbiome (eg, antibiotics during early
childhood).

RESEARCH NEED NO. 2
The gut microbiome plays an essential role in maintaining
health and modification of the microbial communities can have
negative effects in the body. Defining what changes in the
microbiota are associated with acute or chronic adverse effects,
as well as the magnitude of change necessary, is needed.
Adverse effects can range from changes to the intestinal barrier
integrity to alterations or dispersion of the normal microbiota of

the host population of microbiota leading to a diseased state.
Identification of such adverse effects may provide biomarkers
of disease progression. To begin to identify causes and effects of
changes in the microbial population, 2 approaches are possible.
One is to start from a healthy individual’s baseline microbiome
then determine deviations associated with a disease state. The
second is determining what is a diseased state and ascertaining
if there are key nodes, drivers, or contributing factors that move
individuals from health to illness.
Despite the improvements in analytical, genomic, and bioinformatic techniques related to structure and function of the
microbiome in health and disease, there is still a knowledge gap
in the translation of high-throughput data from genotype to
phenotype and microbiome composition stability/instability
versus core function of the microbial community.

KEY ISSUE NO. 3: ACCOUNTING FOR
BIOTRANSFORMATION
GI microbiota have the capacity to metabolize endogenous and
exogenous compounds. The metabolites can have positive, neutral, or negative effects on the host. Endogenous microbial
metabolites can exert physiological functions. Gut microbederived metabolites can signal via receptors at the epithelium
interface and communicate with the host. For example, microbial metabolism of tryptophan generates aryl hydrocarbon receptor (AHR) ligands, such as indole, indirubin, and indigo
(Hubbard et al., 2015). These ligands activate AHR and promote
intestinal homeostasis through regulation of innate cytokine or
chemokine gene expression, regulation of enterocyte differentiation, as well as regulation and development of intraepithelial
lymphocytes and innate lymphoid cells. Gut microbial metabolism can result in products associated with adverse health and
disease progression. The microbiome converts dietary lipid
phosphatidylcholine to trimethylamine (TMA), which is then
metabolized by hepatic flavin monooxygenases to TMA-Noxide (TMAO). TMAO is a proatherogenic factor associated with
cardiovascular disease (CVD; Brown and Hazen, 2015). Such
findings suggest that endogenous microbial metabolites could
be used as potential biomarkers of health or disease.
GI microbiota express biotransformation enzymes that metabolize a variety of therapeutic drugs and environmental compounds that can result in changes in efficacy and toxicity
(Klaassen and Kui, 2015; Spanogiannopoulos et al., 2016). Gut
bacteria can convert a prodrug to an active drug or detoxify the
parent compound leading to modified drug availability, as well
as changes in pharmacokinetics-pharmacodynamics (PKPDs).
Sulfasalazine, a prodrug for ulcerative colitis, is directly metabolized by the gut bacteria at the azo bond to generate 2 bioactive
metabolites, sulfapyridine (antimicrobial) and 5-aminosalicylate (anti-inflammatory; Peppercorn and Goldman, 1972). The
cardiac drug glycoside digoxin undergoes reduction to an inactive metabolite, dihydrodigoxin, which is significantly decreased if antibiotics are preadministered (Haiser et al., 2013;
Lindenbaum et al., 1981). Microbial metabolites of a drug can
also increase toxicity. The chemotherapeutic drug irinotecan is
metabolized to SN-38 which is both the active and toxic metabolite. SN-38 is formed and glucuronidated by the liver and then
transported to the gut where it undergoes deconjugation by gut
bacteria. This results in longer gastrointestinal (GI) exposure,
reabsorption, and greater bioavailability of SN-38 (Wallace et al.,
2010). The gut microbiome is also implicated in the interindividual variability in metabolism of the analgesic and antipyretic
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acetaminophen. The endogenous microbial metabolite p-cresol
and acetaminophen are substrates for sulfotransferases.
Individuals with high levels of p-cresol generated by bacteria
may have decreased acetaminophen metabolism through competition for hepatic sulfonation, which could result in an elevated risk for acetaminophen-induced hepatotoxicity (Clayton
et al., 2009).
Nontherapeutic drugs and environmental xenobiotics can
induce compositional changes and functional changes an in gut
microbiota. In turn, these compounds may also be biotransformed by the microbiome. Arsenic is metabolized by gut bacteria and also alters the abundance and profile of the gut
microbiome (Chi et al., 2018; Gokulan et al., 2018; Lu et al., 2014).
Polychlorinated biphenyl or polybrominated diphenyl ether exposed mice show altered bile acid homeostasis resulting in part
from changes in gut microbiota bile acid metabolism (Cheng et
al, 2018; Li et al, 2018). Gut anaerobes are capable of transforming Hg2þ to highly toxic and permeable methylmercury and significantly contributing to its body burden and poisoning
(Edwards and McBride, 1975).
In addition to directly biotransforming chemicals, the gut
microbiome can influence the host xenobiotic metabolizing capability. Comparison of hepatic drug metabolizing genes in conventional and germ-free (GF) mice show that 34 genes, including
Cyp3a, decrease, whereas 21 genes, including Cyp4a, increase
(Selwyn et al., 2015). A cluster of 112 hepatic genes linked to xenobiotic metabolism and retinoid X receptor-inhibiting pathways are differentially expressed in conventional and GF mice.
This results in more efficient pentobarbital metabolism and
shorter anesthesia time in GF mice (Bjorkholm et al., 2009).

RESEARCH NEED NO. 3
Current experimental approaches to evaluate microbe-mediated
biotransformation primarily include: (1) in vitro incubation of individual bacterial strains, mixed cultures in bioreactors, or purified enzymes with compounds, (2) ex vivo incubation of a fecal
microbiome community (or other GI regions of interest) with
compounds, and (3) in vivo administration of compounds into
animals such as rodents. These approaches provide evidence in
support of microbial metabolism of many approved drugs (Sousa
et al., 2008; Zimmermann et al., 2019). However, more caution is
required when extrapolating these results into humans than
with traditional PKPD approaches, given the high diversity and
interindividual variability of the human gut microbiome.
Comprehensive and accurate modeling approaches for analyzing
microbial metabolism information and incorporating into host
PKPD models are necessary.
As more information on biotransformation of xenobiotics by
the microbiome is published, a public database would be valuable. Such a database would be a repository centralizing comprehensive data that identifies compounds, responsible
bacteria and/or enzymes, metabolites generated and metabolic
pathways. This requires a collaborative effort involving
researchers from academia, government and industry, working
together with the regulatory agencies to promote a better understanding of microbiome-mediated biotransformation.
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in microbial metabolites, or as a consequence of microbial biotransformation of xenobiotics would be useful. There are a number of characteristics for an ideal biomarker. It should be able to
differentiate between disease progression and/or response to
treatment. Stool samples or accessible tissues and/or biofluids
should be used and analysis be affordable to facilitate acceptance and use for large scale screening. The biomarker needs to
work for high-risk populations and distinguish between the disease and other potentially microbiome-mediated effects.
There are some examples of microbiome biomarkers of disease that are promising. Alterations in gut microbiota are associated with hypertension. Exposure of hypertensive rats to the
antibiotic minocycline attenuates blood pressure (Yang et al.,
2015). In animals and humans systolic blood pressure is correlated with microbiota composition and metabolites, as well as
alterations in gut structure (Kim et al., 2018). Zonulin, a bacterial
product and a marker of intestinal permeability, is elevated
with high systolic blood pressure but is not an ideal biomarker
since it is also associated with celiac disease (Fasano et al., 2000;
Kim et al., 2018). A more specific indicator may be the negative
correlation of butyrate producing bacteria which alter systolic
blood pressure and plasma butyrate levels (Kim et al., 2018).
TMAO blood levels are of interest as a biomarker for CVD, insulin resistance, and type 2 diabetes (Miao, 2015). The production
of TMAO in mammals primarily occurs via gut bacteria. Studies in
humans and animals show circulating levels of TMAO are associated with risk and progression of CVD (Tang et al., 2014). Sensitive
assays, particularly those amenable to the clinical setting, are being developed which will facilitate use of TMAO as a biomarker
(Garcia et al, 2017). The initial association of TMAO with CVD
resulted from using untargeted metabolomics in cardiac patients
(Wang et al., 2011). This approach can be expanded to use multiple
data streams (clinical tests, metabolomes, proteomes, genome sequence, and microbiome) to develop correlation networks in order
to identify bacterial analytes associated with normal physiology
or disease (Price et al., 2017). For example, there is an association
between phenylacetylglutamine and the Coriobacteriaceae and
Mogibacteriaceae families. Phenylacetylglutamine is a microbial
metabolite and is a risk factor for CVD in those with chronic kidney disease (Poesen et al., 2016).
Microbial biomarkers may also prove useful for identifying
xenobiotic toxicity. Low dose exposure of mice to polychlorinated biphenyls alters microbiota composition leading to a
greater abundance of species that generate secondary bile acids
causing increases in serum bile acids (Cheng et al., 2018). At
higher doses serum bile acids were not affected due to an increase in hepatic efflux transporters (Cheng et al., 2018).
Although in vivo studies are useful for discovering biomarkers,
there is also a need for in vitro methods. In mice, tempol acts as an
antioxidant by detoxifying reactive oxygen species and modulates
the gut microbiome host signaling axis resulting in prevention of
weight gain (Cai et al., 2016; Li et al., 2013). Incubation of mouse cecal content with tempol and analysis of samples using flow cytometry as well as high-throughput mass spectrometry and
nuclear magnetic resonance-based metabolomics show that tempol disrupted microbiota membrane physiology and metabolic activity consistent with the in vivo data (Cai et al., 2016). Such a multiprong in vitro approach holds promise for screening xenobiotics for
gut microbial toxicity and identifying potential biomarkers.

KEY ISSUE NO. 4: DETERMINING BIOMARKERS
OF DISEASE AND TOXICITY

RESEARCH NEED NO. 4

Biomarkers of disease and toxicity resulting from perturbations
of the gut microbiota composition and function, from changes

Case studies provide examples of potential biomarkers that
could serve as the basis for noninvasive diagnostic tests to
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identify disease and track its progression. When an association between a disease and gut microbiota is recognized, additional work will be needed to distinguish between microbial
changes that are a cause or a result of the disease. Biomarkers
should also be applicable beyond their discovery cohorts and
be able to distinguish between disease states of interest and
nontarget diseases, as well as having a reasonable degree of
specificity.
Discovery and qualification of biomarkers will also be advanced by the adoption of standard protocols which will generate robust and reproducible data that facilitates comparisons of
studies. Detailed methods and procedures for analysis of gut
microbiota structure and function that will be useful for toxicologic studies are available (Nichols et al., 2018).

KEY ISSUE NO. 5: OPTIMIZING ANIMAL
MODELS
Although animal species have limitations in completely replicating humans, they provide an opportunity to manipulate host
genetics and the environment to allow insight into the relationship between the microbiota, xenobiotics, toxicity, and disease.
Although species differences must be recognized in extrapolating animal studies to humans, such data are valuable.
Rodents are widely used in studying the microbiome. The
compositions of gut microbiota vary among genetically distinct
strains of mice (Friswell et al., 2010). Differences also occur in
laboratory strains compared with genetically similar wild populations (Rosshart et al., 2017). GF mice and gene-knockout mice
are also useful models. GF mice can be colonized with a single
(mono-associated) agent, a defined bacterial combination such
as altered Schardler flora or human fecal samples (De Palma
et al., 2017; Franklin and Ericsson, 2017; Orcutt et al., 1987;
Ridaura et al., 2013). Interestingly, introducing microbiota from
wild mice into laboratory mouse strains increases resistance to
influenza infection, decreases inflammation and increases resistance to certain types of cancer (Rosshart et al., 2017). The
wild mouse microbiome develops as a result of evolutionary
pressures due to continuous exposure to natural toxins and
pathogens, thus it may offer a better model for human disease
(Rosshart et al., 2017).
Disparities in gut microbiota of the same mouse strain can
be attributed to vendor or institutional location (Friswell et al.,
2010). Within a facility, the room, cage housing, food, water, and
bedding all have an effect (Ericsson et al., 2018; Friswell et al.,
2010; Hildebrand et al., 2013; Hugenholtz and de Vos, 2018;
Robertson et al., 2019).
Although rodents are the most commonly used models in
microbiome studies, zebrafish are also proving to be useful.
Zebrafish develop rapidly and externally to the mother, thereby
enabling direct embryo exposures. The GI tract is homologous
to that in mammals, although there are differences in the immune system. Zebrafish are kept at a lower temperature than
mammals which may compromise the ability to study humanrelevant microorganisms. Xenobiotic-microbiome interactions
can be evaluated in the zebrafish model. For example, exposure
of zebrafish larvae to the antimicrobial compound triclosan
results in changes in the community structure of the microbiome. There is an increase in triclosan resistant species which
results in a greater ability to biotransform triclosan (Weitekemp
et al., 2019). Gut microbiota in zebrafish also alter metabolism
and mediate the neurodevelopmental toxicity of 17-b-estradiol
(Catron et al., 2019).

RESEARCH NEED NO. 5
Study reproducibility in the biosciences is an ongoing concern
(Mullane and Williams, 2017). Variations in experimental design, methods, and statistical analysis can contribute to an inability to replicate results and conclusions. Complicating this
further is the diversity and function of the gut microbiota
(Franklin and Ericsson, 2017; Turner, 2018).
Reproducibility in studies of gut microbiome host dynamics
can be increased by recognizing the sources of variation, prioritizing them; then, identifying ways to address them (Ericsson
and Franklin, 2015; Franklin and Ericsson, 2017). To limit variation in mouse models, numerous approaches have been developed to standardize gut microbiota profiles including
cohousing, cross fostering, and GF derivation, although each
has advantages and disadvantages (Ericsson and Franklin, 2015;
Franklin and Ericsson, 2017). Maintaining a stable microbiome
composition across animals and experiments is a problem that
is not easily solved. Banking fecal samples annually and defining the microbiome at the initiation of a study would allow institutional drift to be monitored (Franklin and Ericsson, 2017). In
some instances, repeating studies in the second generation
addresses the need for exposure to microbiota in early development (Franklin and Ericsson, 2017). For zebrafish, protocols for
GF derivation and gnotobiotic husbandry provide useful guidance for standardization (Melancon et al., 2017).
Often the discrepancies in reported results can be attributed
to variations in study design. Unfortunately, key details are often missing from publications. Omissions can be reduced by
adoption of Animal Research: Reporting of Experiments guidelines (Kilkenny et al., 2012). This checklist of 20 items covers species, strain and number of animals, husbandry, experimental
design, methods, and statistical analysis.
Determining the optimal microbiota to facilitate translating
results from mice to humans depends on the question being
asked. The current model of colonizing GF mice with microbiota
derived from inbred, wild murine, or human sources has great
potential. This approach is currently limited by the availability
of the number of defined combinations and characterized
mouse or human material. The development of a wider array of
standardized samples would be useful.
Several in vitro models of host-microbiome interactions have
been described that complement in vivo studies (Arnold et al.,
2016; von Martels et al., 2017). Although there are anaerobic bacteria gut epithelial cell cocultures showing feasibility for experimental use, further refinements and standardization are still
necessary (von Martels et al., 2017). It is also recognized that no
one model is perfect, the best one to use will depend on the
question being addressed.

RECOMMENDATIONS
The gut microbiome plays a pivotal part in health, but understanding its multiple roles still needs to be fully elucidated. HESI’s
gut microbiome workshop was convened to identify research
areas critical to determining how gut microbiome alterations
may influence human health. Data gaps and research needs to
address specific issues have been identified based on workshop
presentations and breakout group discussions (Table 2).
There are 2 topics that cut across the key issues. The first is
the lack of clarity in what constitutes gut microbiomes in
healthy individuals. It is recognized that there are many factors
that contribute to variation across and within human populations. Consequently, there is not a single microbiome but rather
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Table 2. Key Issues and Research Needs
Key Issue
Defining gut microbiomes
associated with health

Defining causes and effects
altering the gut microbiome

Accounting for
biotransformation
Determining biomarkers of
disease and toxicity

Research Needs
•
•
•
•
•
•
•
•

•
•
•
•
•

•
Optimizing animal models

•
•
•

•

Identify composition and functional requirements of the microbiota community
Develop guidelines for the normal range of variation
Determine the effects of host factors
Standardize samples collection procedures
Identify changes in species composition and function associated with disease
Define the magnitude of changes required
Determine the effects on host organ systems
Understand mechanisms affecting host susceptibility to diseases and adverse
effects correlated with microbiota
• Factors impacting the microbiome
• Factors impacting the host
Characterize biotransformation enzymes in microbiota species
Identify endogenous and exogenous substrates of microbiota enzymes
Develop and maintain a public database of compounds, microbiota, and metabolites generated
Identify and characterize microbiota metabolites associated with disease and toxicity
Characterize developed biomarkers
• Specificity
• Applicability to individuals and populations
Develop reliable and inexpensive analytical methods for these biomarkers to facilitate translation
from the research laboratory to a clinical setting
Standardize husbandry practices that influence microbiome composition and function
Adopt practices that facilitate comparison and reproducibility of studies
Identify the impact of the source of the microbiome in mouse models
• Wild mice
• Laboratory mice
• Human
Refine in vivo and in vitro models of host-microbiome interactions

Key research areas and needs, as identified by workshop speakers and participants who participated in breakout group discussions.

a suite of microbiomes that are associated with health. As yet,
these have not yet been adequately defined. Having information
on which species comprise such microbiomes and the normal
range of variation is critical in order to define disease and adverse effects. The second is the need to adopt standards for
methods, models and data analysis. This will facilitate comparisons across studies and reproducibility of data.
Moving forward the key recommendations are to focus
efforts on the following important areas:
• Defining the range of gut microbiota composition and function
gut microbiomes associated with health and/or disease;
• Identifying microbiome changes linked to disease and adverse
health effects;
• Characterizing the formation and function of microbiota metabolism of endogenous products on health and disease;
• Determining the effects of xenobiotics on microbiota composition and function;
• Increasing understanding of the impact of microbiota biotransformation of xenobiotics on efficacy and toxicity;
• Identifying a suite of biomarkers to monitor health, disease and
adverse effects resulting from microbiota-host interactions;
• Standardizing variables such as husbandry, study design, sample
collection, analysis, and statistical methods

Addressing these issues will provide further insight into the
role of the microbiome in human health, disease and toxicity.

helps to resolve global and environmental challenges by
convening experts through multi-sector forums. HESI’s
work aims to move scientific principles into tested solutions
that can be broadly applied to benefit health and the environment. The authors gratefully acknowledge the contributions of the speakers and the workshop participants, the
discussions of which form the basis for this article. The
views expressed in this article are those of the authors and
do not necessarily reflect the views or policies of the author
employers.
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